September 27, 2019
Pfizer’s study of investigational Oral JAK1 candidate in Abrocitinibfor Severe Atopic Dermatitis hits targets
Pfizer’s study of investigational Oral JAK1 candidate in Abrocitinibfor Severe Atopic Dermatitis hits targets achieves all co-primary and key secondary endpoints, as safety results show both doses of abrocitinib consistent with prior clinical trial experiences.